- Previous Rank57
- Revenues ($M)$53,647.0
- Revenue Percent Change2.1%
- Profits ($M)$11,153.0
- Profits Percent Change-47.7%
- Assets ($M)$159,422.0
- Employees92,400
In Ian Read’s final year as the company’s CEO, Pfizer managed to grow revenues by just 2% as it adjusted to greater competition to—and diminished sales of—Viagra and other drugs on which the company lost patent exclusivity in 2017. The pharmaceutical giant is now in the midst of a reorganization since announcing in the summer of 2018 that it would separate its business into three parts, one of which (its consumer health division) it plans to merge into a joint venture with GlaxoSmithKline. The moves are designed to position Pfizer for greater sales growth under new CEO Albert Bourla.
Company Info
| CEO | Albert Bourla |
| CEO Title | Chief Executive Officer & Director |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | New York, N.Y. |
| Website | http://www.pfizer.com |
| Years on Fortune 500 List | 65 |
| Employees | 92,400 |
Looking for leads, investment insights, or competitive intelligence?Purchase Now
Pfizer Rank History
placeholder
Key Financials (Last Fiscal Year)
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | $53,647.0 | 2.1% |
| Profits ($M) | $11,153.0 | -47.7% |
| Assets ($M) | $159,422.0 | - |
| Total Stockholder Equity ($M) | $63,407.0 | - |
Profit Ratios
| Profit as % of Revenues | 20.8% |
| Profits as % of Assets | 7.0% |
| Profits as % of Stockholder Equity | 17.6% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 1.87 |
| EPS % Change (from 2017) | -46.9% |
| EPS % Change (5 year annual rate) | -10.1% |
| EPS % Change (10 year annual rate) | 4.5% |
Total Return
| Total Return to Investors (2018) | 24.7% |
| Total Return to Investors (5 year, annualized) | 11.2% |
| Total Return to Investors (10 year, annualized) | 13.8% |